Format

Send to

Choose Destination
Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106.

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Author information

1
CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.
2
Department of Haematology, Institut Universitaire du Cancer, Toulouse, France.
3
Boehringer Ingelheim RCV GmbH & Co KG, Wien, Austria.
4
Institut Universitaire du Cancer, Bureau d'études cliniques, Toulouse, France.
PMID:
27834943
PMCID:
PMC5148053
DOI:
10.1038/bcj.2016.106
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center